“We are grateful for the Phase 2 SBIR grant from the NIH for S-969, a continuation of our initial grant supporting the advancement of S-969 through early pre-clinical studies,” said Ryan Wuebbles, Ph.D., Chief Science Officer, Strykagen. “This grant allows us to evaluate the efficacy of S-969 in standard dose ranging models and complete IND enabling actions before entering the clinic.”

Sarcomatrix President and CEO, David Craig, MBA added, “With this funding, we aim to further showcase the therapeutic promise of disrupting the muscular dystrophy market with our first-in-class oral small molecule drugs.”

Research reported in this publication was supported by the Office of The Director, National Institutes of Health of the National Institutes of Health under Award Number 2R44OD030543-04. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.

About S-969

S-969, a first-in-class small molecule with known MOA, targets the underlying molecular mechanisms, aiming to possibly halt or reverse disease progression, with the potential for use alone or in combination to treat muscle wasting diseases.

ABOUT SARCOMATRIX THERAPEUTICS, CORP.

Sarcomatrix Therapeutics, Corp. is a privately held, clinical-stage biotechnology company focused on developing and commercializing potential treatments that regulate integrins and laminins, a missing piece in treating muscle wasting diseases, starting with muscular dystrophies.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, which, aside from historical facts, include future projections subject to significant risks, especially concerning Sarcomatrix’ s development programs. Actual outcomes may differ due to various factors, including funding and regulatory approvals. Sarcomatrix does not commit to updating these statements unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230920341253/en/